Atossa Therapeutics Inc. [NASDAQ: ATOS] stock went on an upward path that rose over 9.57% on Wednesday, amounting to a one-week price increase of more than 4.82%. The company report on July 27, 2020 that Registration Is Now Open for Atossa Therapeutics’ Tribe Public Webinar Presentation and Q&A Event on July 30, 2020.
Atossa’s CEO, Dr. Steven Quay, M.D., Ph.D., will address recent progress with two COVID-19 treatment programs.
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company with a current focus on breast cancer and COVID-19, announces that Atossa’s CEO, Dr. Steven Quay, M.D., Ph.D., will present at Tribe Public’s Zoom Webinar Presentation and Q&A Event that is scheduled to begin at 8am pacific/11am eastern on Thursday, July 30th. During this complimentary, 30-minute event, Dr. Quay will present the company followed by a Q&A session regarding Atossa’s breast cancer development programs and recent progress with its two COVID-19 treatment programs. To register to join the complimentary event, please visit the Tribe Public LLC website: www.tribepublic.com, or send a message to Tribe’s management at firstname.lastname@example.org to request your seat for this limited capacity Zoom-based event.
Over the last 12 months, ATOS stock rose by 114.29%. The average equity rating for ATOS stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $40.32 million, with 9.21 million shares outstanding and 9.18 million shares in the current float. Compared to the average trading volume of 861.28K shares, ATOS stock reached a trading volume of 1313564 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Atossa Therapeutics Inc. [ATOS]:
Maxim Group have made an estimate for Atossa Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 26, 2018.
The Average True Range (ATR) for Atossa Therapeutics Inc. is set at 0.39 The Price to Book ratio for the last quarter was 3.88, with the Price to Cash per share for the same quarter was set at 1.01.
ATOS Stock Performance Analysis:
Atossa Therapeutics Inc. [ATOS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.82. With this latest performance, ATOS shares gained by 10.69% in over the last four-week period, additionally plugging by 191.95% over the last 6 months – not to mention a rise of 114.29% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ATOS stock in for the last two-week period is set at 63.33, with the RSI for the last a single of trading hit 64.77, and the three-weeks RSI is set at 62.68 for Atossa Therapeutics Inc. [ATOS]. The present Moving Average for the last 50 days of trading for this stock 3.32, while it was recorded at 3.99 for the last single week of trading, and 1.95 for the last 200 days.
Insight into Atossa Therapeutics Inc. Fundamentals:
Return on Total Capital for ATOS is now -156.88, given the latest momentum, and Return on Invested Capital for the company is -156.92. Return on Equity for this stock declined to -157.00, with Return on Assets sitting at -131.50. When it comes to the capital structure of this company, Atossa Therapeutics Inc. [ATOS] has a Total Debt to Total Equity ratio set at 0.38. Additionally, ATOS Total Debt to Total Capital is recorded at 0.38, with Total Debt to Total Assets ending up at 0.35. Long-Term Debt to Equity for the company is recorded at 0.09, with the Long-Term Debt to Total Capital now at 0.08.
Reflecting on the efficiency of the workforce at the company, Atossa Therapeutics Inc. [ATOS] managed to generate an average of -$2,873,296 per employee.Atossa Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.80 and a Current Ratio set at 12.80.
ATOS Stock EPS
With the latest financial reports released by the company, Atossa Therapeutics Inc. posted -0.8/share EPS, while the average EPS was predicted by analysts to be reported at -0.48/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -66.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ATOS.
Atossa Therapeutics Inc. [ATOS] Insider Position Details
There are presently around $1 million, or 2.70% of ATOS stock, in the hands of institutional investors. The top three institutional holders of ATOS stocks are: VANGUARD GROUP INC with ownership of 120,689, which is approximately 0% of the company’s market cap and around 0.57% of the total institutional ownership; GEODE CAPITAL MANAGEMENT, LLC, holding 89,903 shares of the stock with an approximate value of $0.39 million in ATOS stocks shares; and VIRTU FINANCIAL LLC, currently with $64000.0 in ATOS stock with ownership of nearly New of the company’s market capitalization.
Positions in Atossa Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 4 institutional holders increased their position in Atossa Therapeutics Inc. [NASDAQ:ATOS] by around 16,418 shares. Additionally, 4 investors decreased positions by around 38,655 shares, while 7 investors held positions by with 185,790 shares. The mentioned changes placed institutional holdings at 240,863 shares, according to the latest SEC report filing. ATOS stock had 4 new institutional investments in for a total of 16,418 shares, while 4 institutional investors sold positions of 38,655 shares during the same period.